Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders (QoQ) (2009 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.15% |
| Mar 31, 2026 | 84.67% |
| Dec 31, 2025 | -61.89% |
| Sep 30, 2025 | 505.22% |
| Jun 30, 2025 | -295.75% |
| Mar 31, 2025 | 78.21% |
| Dec 31, 2024 | 24.92% |
| Sep 30, 2024 | -560.61% |
| Jun 30, 2024 | 74.39% |
| Mar 31, 2024 | 52.18% |
| Dec 31, 2023 | -193.31% |
| Sep 30, 2023 | 153.53% |
| Jun 30, 2023 | -58.54% |
| Mar 31, 2023 | 16.09% |
| Dec 31, 2022 | 48.88% |
| Sep 30, 2022 | -46.33% |
| Jun 30, 2022 | -15.42% |
| Mar 31, 2022 | 7.01% |
| Dec 31, 2021 | -26.38% |
| Sep 30, 2021 | -7.89% |